Literature DB >> 8795569

The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells.

K Berg1, H Anholt, O Bech, J Moan.   

Abstract

Human adenocarcinoma cells of the line WiDr and Chinese hamster lung fibroblasts of the line V79 were treated with 5-aminolaevulinic acid (5-ALA) and exposed to light. The effects of the iron chelators ethylenediaminetetraacetic acid (EDTA) and desferrioxamine (DEF) were assessed. Both cell lines were treated with various concentrations of 5-ALA in the presence or absence of the iron chelators for 4 h in serum-free medium. The accumulation of protoporphyrin IX (PpIX) reached a maximum level at 1 mM 5-ALA in WiDr cells [280 ng PpIX (mg protein x 4 h-1] and at 0.1 mM 5-ALA in V79 cells [55 ng PpIX (mg protein x 4 h)-1]. PpIX was the only fluorescing porphyrin in these cells after 5-ALA treatment alone or in combination with the chelators. The iron chelators did not influence the intracellular localisation pattern of PpIX in 5-ALA-treated cells. While both chelators enhanced the accumulation of PpIX in 5-ALA-treated cells, DEF was found to be superior at equal concentrations. A linear relationship between the applied concentration of DEF and the DEF-induced increase in PpIX accumulation was observed in double-reciprocal plots. The intercepts of the regression lines with the ordinate indicate that the ferrochelatase is saturated with PpIX when the 5-ALA concentration exceeds 0.3 mM and 0.05 mM in WiDr and V79 cells respectively. The DEF-induced enhancement of PpIX accumulation in 5-ALA-treated cells was cell line and 5-ALA concentration dependent. At a 5-ALA concentration inducing a maximum level of PpIX accumulation, inhibition of ferrochelatase activity enhanced the PpIX accumulation 3- and 1.4-fold in V79 and WiDr cells respectively. The relative gain in PpIX accumulation increased with decreasing concentration of 5-ALA. In cells treated with the lowest concentrations of 5-ALA used in this study, DEF enhanced PpIX accumulation 44- and 3.5-fold in V79 and WiDr cells respectively. The iron chelator-induced increase in cellular PpIX accumulation was followed by a similar increase in sensitivity to photoinactivation. The ferrochelatase inhibitor dihydropyridine 3,5-diethoxycarbonyl-1,4-dihydrocollidine reduced the accumulation of PpIX in both cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795569      PMCID: PMC2074689          DOI: 10.1038/bjc.1996.423

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Light induced relocalization of sulfonated meso-tetraphenylporphines in NHIK 3025 cells and effects of dose fractionation.

Authors:  K Berg; K Madslien; J C Bommer; R Oftebro; J W Winkelman; J Moan
Journal:  Photochem Photobiol       Date:  1991-02       Impact factor: 3.421

2.  Photodestruction of tumor cells by induction of endogenous accumulation of protoporphyrin IX: enhancement by 1,10-phenanthroline.

Authors:  N Rebeiz; C C Rebeiz; S Arkins; K W Kelley; C A Rebeiz
Journal:  Photochem Photobiol       Date:  1992-03       Impact factor: 3.421

3.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.

Authors:  J C Kennedy; R H Pottier; D C Pross
Journal:  J Photochem Photobiol B       Date:  1990-06       Impact factor: 6.252

4.  Inhibition of human lymphocyte ferrochelatase activity by hemin.

Authors:  E Rossi; P V Attwood; P Garcia-Webb; K A Costin
Journal:  Biochim Biophys Acta       Date:  1990-05-08

5.  Purification and substrate specificity of bovine liver-ferrochelatase.

Authors:  S Taketani; R Tokunaga
Journal:  Eur J Biochem       Date:  1982-10

6.  The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders.

Authors:  N Schoenfeld; O Epstein; M Lahav; R Mamet; M Shaklai; A Atsmon
Journal:  Cancer Lett       Date:  1988-12-01       Impact factor: 8.679

7.  N-Alkylprotoporphyrin IX formation in 3,5-dicarbethoxy-1,4-dihydrocollidine-treated rats. Transfer of the alkyl group from the substrate to the porphyrin.

Authors:  P R Ortiz de Montellano; H S Beilan; K L Kunze
Journal:  J Biol Chem       Date:  1981-07-10       Impact factor: 5.157

8.  Porphyrin metabolism in some malignant diseases.

Authors:  M M el-Sharabasy; A M el-Waseef; M M Hafez; S A Salim
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

9.  The detection of phthalocyanine fluorescence in normal rat bladder wall using sensitive digital imaging microscopy.

Authors:  A J Pope; A J MacRobert; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

10.  Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins.

Authors:  Z Malik; H Lugaci
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

View more
  27 in total

1.  Review of Neurosurgical Fluorescence Imaging Methodologies.

Authors:  Brian W Pogue; Summer Gibbs-Strauss; Pablo A Valdés; Kimberley Samkoe; David W Roberts; Keith D Paulsen
Journal:  IEEE J Sel Top Quantum Electron       Date:  2010-05       Impact factor: 4.544

2.  Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine.

Authors:  Pratheeba Palasuberniam; Daniel Kraus; Matthew Mansi; Alexander Braun; Richard Howley; Kenneth A Myers; Bin Chen
Journal:  Photochem Photobiol       Date:  2019-03-15       Impact factor: 3.421

Review 3.  Optical technologies for intraoperative neurosurgical guidance.

Authors:  Pablo A Valdés; David W Roberts; Fa-Ke Lu; Alexandra Golby
Journal:  Neurosurg Focus       Date:  2016-03       Impact factor: 4.047

Review 4.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

5.  Suppression of iron mobilization from lysosomes to mitochondria attenuates liver injury after acetaminophen overdose in vivo in mice: Protection by minocycline.

Authors:  Jiangting Hu; John J Lemasters
Journal:  Toxicol Appl Pharmacol       Date:  2020-02-25       Impact factor: 4.219

6.  Iron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones.

Authors:  Anna Mrozek-Wilczkiewicz; Maciej Serda; Robert Musiol; Grzegorz Malecki; Agnieszka Szurko; Angelika Muchowicz; Jakub Golab; Alicja Ratuszna; Jaroslaw Polanski
Journal:  ACS Med Chem Lett       Date:  2014-01-23       Impact factor: 4.345

7.  Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model.

Authors:  Pablo A Valdés; Kimberley Samkoe; Julia A O'Hara; David W Roberts; Keith D Paulsen; Brian W Pogue
Journal:  Photochem Photobiol       Date:  2009-12-07       Impact factor: 3.421

8.  Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery.

Authors:  Annika Johansson; Christer Möller; Pauline Harper
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

9.  Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.

Authors:  Andrew Pye; Sandra Campbell; Alison Curnow
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-01       Impact factor: 4.553

10.  Autoradiographic and scintillation analysis of 5-aminolevulinic acid permeation through epithelialised tissue: implications for topical photodynamic therapy of superficial gynaecological neoplasias.

Authors:  Paul A McCarron; Ryan F Donnelly; A David Woolfson
Journal:  Pharm Res       Date:  2007-07-27       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.